241 related articles for article (PubMed ID: 12376518)
41. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
42. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
43. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
44. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
45. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
46. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
48. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
49. Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec.
Dorval M; Noguès C; Berthet P; Chiquette J; Gauthier-Villars M; Lasset C; Picard C; Plante M; ; ; Simard J; Julian-Reynier C
Eur J Hum Genet; 2011 May; 19(5):494-9. PubMed ID: 21248744
[TBL] [Abstract][Full Text] [Related]
50. Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result.
Brédart A; Kop JL; De Pauw A; Caron O; Fajac A; Noguès C; Stoppa-Lyonnet D; Dolbeault S
Breast; 2017 Feb; 31():121-127. PubMed ID: 27837705
[TBL] [Abstract][Full Text] [Related]
51. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
[TBL] [Abstract][Full Text] [Related]
52. Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study.
Plon SE; Peterson LE; Friedman LC; Richards CS
Genet Med; 2000; 2(6):307-11. PubMed ID: 11339650
[TBL] [Abstract][Full Text] [Related]
53. The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal?
Beran TM; Stanton AL; Kwan L; Seldon J; Bower JE; Vodermaier A; Ganz PA
Ann Behav Med; 2008 Oct; 36(2):107-16. PubMed ID: 18787910
[TBL] [Abstract][Full Text] [Related]
54. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample.
Schwartz MD; Peshkin BN; Hughes C; Main D; Isaacs C; Lerman C
J Clin Oncol; 2002 Jan; 20(2):514-20. PubMed ID: 11786581
[TBL] [Abstract][Full Text] [Related]
55. The problems with risk selection; scientific and psychosocial aspects.
Hartman AR
Recent Results Cancer Res; 2005; 166():125-44. PubMed ID: 15648188
[TBL] [Abstract][Full Text] [Related]
56. Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
Carmichael H; Matsen C; Freer P; Kohlmann W; Stein M; Buys SS; Colonna S
Breast Cancer Res Treat; 2017 Apr; 162(2):225-230. PubMed ID: 28138892
[TBL] [Abstract][Full Text] [Related]
57. Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study.
Gierach GL; Li H; Loud JT; Greene MH; Chow CK; Lan L; Prindiville SA; Eng-Wong J; Soballe PW; Giambartolomei C; Mai PL; Galbo CE; Nichols K; Calzone KA; Olopade OI; Gail MH; Giger ML
Breast Cancer Res; 2014; 16(4):424. PubMed ID: 25159706
[TBL] [Abstract][Full Text] [Related]
58. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
Kriege M; Brekelmans CT; Boetes C; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Manoliu RA; Holland R; de Koning HJ; Klijn JG
Fam Cancer; 2001; 1(3-4):163-8. PubMed ID: 14574173
[TBL] [Abstract][Full Text] [Related]
59. Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
Evans DG; Lennard F; Pointon LJ; Ramus SJ; Gayther SA; Sodha N; Kwan-Lim GE; Leach MO; Warren R; Thompson D; Easton DF; Eeles R;
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2123-31. PubMed ID: 19567506
[TBL] [Abstract][Full Text] [Related]
60. Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred.
Kinney AY; Simonsen SE; Baty BJ; Mandal D; Neuhausen SL; Seggar K; Holubkov R; Bloor L; Smith K
J Genet Couns; 2006 Aug; 15(4):293-305. PubMed ID: 16865561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
